Navigation Links
Phase IIb Study of Vanoxerine Shows Strong Safety and Statistically Significant Efficacy Signals for Treatment of Atrial Fibrillation
Date:11/18/2013

DALLAS, Nov. 18, 2013 /PRNewswire/ -- ChanRx, a pharmaceutical company developing medicines for cardiovascular diseases, today announced positive safety and statistically significant efficacy data from a Phase IIb study of vanoxerine (GBR-12909), a drug in development for the treatment of atrial fibrillation. The data were presented yesterday at the American Heart Association 2013 Scientific Sessions.

"Atrial fibrillation affects millions of patients in the US annually, causing substantial morbidity," said Peter Kowey, MD, Professor of Medicine & Pharmacology, Jefferson School of Medicine and Lankenau Institute for Medical Research. "Currently, drugs that correct this arrhythmia are inadequate and carry safety risks including life threatening arrhythmias, long-term toxicity and liver failure. Both the patients with this condition and the physicians treating them could benefit greatly from a drug that could safely treat this arrhythmia."

In the randomized, placebo-controlled trial, 104 patients presenting with symptomatic atrial fibrillation or atrial flutter of recent onset were assigned to one of three doses of vanoxerine or placebo. Vanoxerine was found to be well tolerated at all doses.  Importantly, no episodes of monomorphic or polymorphic ventricular tachycardia were seen. Ventricular tachycardia is a potentially life-threatening arrhythmia that can lead to sudden death. The majority of currently marketed drugs used for atrial fibrillation have a risk of polymorphic ventricular tachycardia.

"Historically, drugs to treat atrial fibrillation have failed, not because they are ineffective, but because they have significant safety issues," noted Arthur "Buzz" Brown, MD, PhD, founder and CEO of ChanTest and founder and CSO of ChanRx. "Thus far, the clinical data showing a lack of pro-arrhythmic effects for vanoxerine are extremely promis
'/>"/>

SOURCE ChanRx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Jan. 14, 2014 InformEx, North America,s ... high-value chemistry, will hold the 30 th edition of ... Convention Center from January 21-24. (Logo: ... top pharmaceutical, fine chemical and specialty chemical companies will take ...
(Date:1/14/2014)... 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC Screw System - ... instrumentation to place and insert the screw accurately - ... (e.g. ligament) repair or reconstruction as it holds the ... (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) The SLIC ...
(Date:1/14/2014)... , Jan. 14, 2014 NineSigma , Inc., ... its Innovation Leadership Summit , May 14-16, 2014 ... Cleveland Ohio . This ... organizations committed to breakthrough achievements through open innovation. Participants ...
Breaking Medicine Technology:Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
... Japanese Study Suggests the Drug Improves Memory, SARASOTA, ... announced today that it has received positive,preliminary results ... a,promising new drug application for the treatment of ... in,September, is the first human clinical study conducted ...
... treated with maximally,tolerated lipid-lowering therapies experienced 50% ... other atherogenic,when treated with 300 mg/week ISIS ... 26, 2007,/PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. announced,results ... of ISIS 301012 in,patients with homozygous familial ...
Cached Medicine Technology:Sarasota's Roskamp Institute Announces Positive Safety Data in,Human Clinical Study for Alzheimer's Disease 2Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012,in Familial Hypercholesterolemia Patients Presented at ACC 2Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012,in Familial Hypercholesterolemia Patients Presented at ACC 3Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012,in Familial Hypercholesterolemia Patients Presented at ACC 4Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012,in Familial Hypercholesterolemia Patients Presented at ACC 5Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012,in Familial Hypercholesterolemia Patients Presented at ACC 6
(Date:4/18/2014)... news release is available in French . ... could revolutionize surgical practice and regenerative medicine. A team ... et Chimie (CNRS/ESPCI Paris Tech) and Didier Letourneur from ... Paris 13), has just demonstrated that the principle of ... in vivo to repair soft-tissue organs and tissues. This ...
(Date:4/17/2014)... inflammation in benign prostate tissue was associated with ... was found even in those with low prostate-specific ... in Cancer Epidemiology, Biomarkers & Prevention , ... Research. , An analysis of prostate tissue biopsies ... of the Prostate Cancer Prevention Trial (PCPT) found ...
(Date:4/17/2014)... variant specifically associated with the risk of a ... cent of all breast cancer cases. , The ... called invasive lobular carcinoma, gives researchers important clues ... of breast cancer, which can be missed through ... the journal PloS Genetics , was co-led ...
(Date:4/17/2014)... CHAMPAIGN, Ill. One of the most popular vaccine ... choice. And doctors may be overlooking some cost factors ... actually a more expensive option, according to a new ... of vaccines to administer can be driven by numerous ... study and a professor of computer science and of ...
(Date:4/17/2014)... April issue of Experimental Biology and Medicine ... Rex Gaskins and Paul Kenis in the Institute ... the University of Illinois Urbana-Champaign describe their recent ... underlie a variety of cell functions including energy ... crucial roles in regulating normal cellular behavior, redox ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study recalculates costs of combination vaccines 2Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2
... have a decreased risk of developing diabetes, according to ... The study found that// only 8 percent of the ... percent of those on older drugs. ,The ... Norvasc and Coversyl with a beta-blocker and a diuretic. ...
... The Journal of the American Medical Association finds that ... as ever. Doctors' training, or// residency includes shifts that ... Council for Graduate Medical Education (ACGME) say that they ... MPH, of Harvard Medical School, and colleagues said that ...
... the September issue of Archives of Pediatrics & Adolescent Medicine, ... prepared in the event of a conflict// and have trained ... need urgent medical care. The report is based on the ... ,Military hospitals are likely to encounter injured children as wars ...
... of Japan, who gave birth to a male heir today, ... for transplantation to leukemia patients, Masao// Nakabayashi, director of Aiiku ... Princess Kiko made the offer after she gave birth by ... on her request," Nakabayashi told reporters. Experts say that the ...
... leader in oral care, in association with the Indian ... observed as Oral Health Month. Now in its third ... oral health awareness campaign in India to establish and ... all ages. This year, the theme of Oral Health ...
... the pizza melts away in your mouth, you might just ... in this delicious spread.// A novel study has served the ... calorie content of fast-food meals. Although the estimations were accurate ... ,Pierre Chandon, a co-author of the study ...
Cached Medicine News:Health News:Military Hospitals Need To Be Prepared To Treat Children 2Health News:Striving to Make India Free from Tooth Decay 2
Surgitie&trade Single Use Ligating Loops with Delivery System...
Surgitie&trade Single Use Ligating Loops without Delivery System with POLYSORB™....
ENDO STITCH&trade Triple-Stitch Single Use Loading Units for use with ENDO Stitch* 10 mm Suturing Device....
ENDO STITCH™ Single Use Loading Units....
Medicine Products: